FAP and neoplasm: By studying the pharmacokinetics of the ADC in vivo, the optimal irradiation timing was determined.In the 4T1-FAP subcutaneous tumor-bearing mice, after treatment with4 Gy, MMAE was efficiently released from the ADC at a concentrationof approximately 120 nM, leading to significant inhibition of tumorgrowth (Figure c–f).